{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:24:05Z","timestamp":1792081445534,"version":"4.4.0"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive and lethal cancers, with high incidence and mortality rates in East Asia. Neoadjuvant chemotherapy (NC) has traditionally been the standard approach for improving resectability in ESCC, but its limited efficacy in achieving complete pathological responses and enhancing survival has driven interest in combining it with immune checkpoint inhibitors (ICIs), resulting in neoadjuvant chemoimmunotherapy (NIC). Based on randomized controlled trials (RCTs), this meta-analysis compares the risks and clinical benefits of NIC versus NC in resectable ESCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This meta-analysis systematically reviewed data from randomized controlled trials (RCTs) comparing NIC and NC in the treatment of resectable ESCC. Primary outcomes included pathological complete response (pCR) and major pathological response (MPR), while secondary outcomes focused on overall survival (OS), event-free survival(EFS), surgery rate, microscopically margin-negative resection(R0 resection), Intraoperative and hospitalization indicators, T Staging, Response evaluation criteria in solid tumors(RECIST), and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six high-quality RCTs (1070 patients) were included. NIC significantly improved major pathological response(MPR) (42.8% vs. 22.2%, Odds Ratio(OR) = 2.40, p = 0.0007) and pathological complete response(pCR) (22.2% vs. 8.0%, OR\u00a0=\u00a03.53, p &amp;lt; 0.00001). NIC was also associated with borderline statistically significant improvements in overall survival (OS) (HR\u00a0=\u00a00.57, p = 0.05) and R0 resection rate (OR\u00a0=\u00a02.56, p = 0.05). In addition, NIC enhanced surgical rate (OR\u00a0=\u00a01.57, p = 0.02), lymph node resection (Mean Difference (MD) = 1.76, P\u00a0=\u00a00.008), and NIC with a longer interval to surgery (MD\u00a0=\u00a04.73, p = 0.003, I2\u00a0=\u00a095%), although this pooled estimate is less reliable because of considerable heterogeneity. However, immune-related adverse events (iRAEs) were higher in NIC (23.21% vs. 1.16%, p &amp;lt; 0.00001), though severe AEs were similar.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NIC significantly improves pathological response and other perioperative benefits (e.g., surgical rate and lymph node resection) in resectable ESCC compared with NC, with a trend toward improved survival, despite a higher incidence of irAEs. Further studies are needed to optimize treatment protocols and clarify the long-term impact of immune-related toxicities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1825905","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:36:11Z","timestamp":1783575371000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Yibang","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuliang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taidui","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University","place":["Fuzhou, China"]},{"name":"National Key Clinical Specialty of Thoracic Surgery","place":["Fuzhou, China"]},{"name":"Clinical Research Center for Thoracic Tumors of Fujian Province","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","article-title":"The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020","volume":"163","author":"Morgan","year":"2022","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/1759-7714.14835","article-title":"Epidemiological landscape of esophageal cancer in Asia: results from GLOBOCAN 2020","volume":"14","author":"Zhu","year":"2023","journal-title":"Thorac Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i20.2638","article-title":"Latest insights into the global epidemiological features, screening, early diagnosis and prognosis prediction of esophageal squamous cell carcinoma","volume":"30","author":"Zhao","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00866","article-title":"Treatment of locally advanced esophageal carcinoma: ASCO guideline","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.06.2998","article-title":"Neoadjuvant therapy approaches for resectable locally advanced esophageal squamous cell carcinoma: a systematic review and network meta-analysis of randomized controlled trials","volume":"123","author":"Lee","year":"2025","journal-title":"Int J Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1186\/s12876-025-04030-7","article-title":"Neoadjuvant chemotherapy with or without PD-1\/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials | BMC gastroenterology | springer nature link","volume":"25","author":"Zhang","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znag012","article-title":"Survival after pathological complete response following neoadjuvant chemotherapy vs chemoradiotherapy in esophageal squamous cell carcinoma","author":"Okui","year":"2026","journal-title":"Br J Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2219591","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in oncology","volume":"12","author":"Sprooten","year":"2023","journal-title":"Oncoimmunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-025-11563-8","article-title":"Short-term intra- and peri-tumoral spatiotemporal CT radiomics for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer","volume":"35","author":"Bao","year":"2025","journal-title":"Eur Radiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.21037\/atm.2017.11.24","article-title":"Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years","volume":"5","author":"Zhang","year":"2017","journal-title":"Ann Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12604","article-title":"Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial","volume":"44","author":"Zheng","year":"2024","journal-title":"Cancer Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12943-025-02332-8","article-title":"Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring","volume":"24","author":"Jiao","year":"2025","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02804-y","article-title":"Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized phase II clinical trial: a randomized clinical trial of neoadjuvant therapy for ESCC","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1139990","article-title":"M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: a pilot study | cochrane library","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1200\/JCO.2023.41.16_suppl.4064","article-title":"Efficacy and safety of\u00a0camrelizumab combined with chemotherapy versus chemotherapy alone as preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma: preliminary results from a multicenter, prospective, randomized controlled study","volume":"41","author":"Zhang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1691998","article-title":"Neoadjuvant chemotherapy versus surgery alone in locally advanced esophageal squamous cell carcinoma: a propensity-matched real-world study","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33976","article-title":"Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study","volume":"151","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"18","author":"Cortazar","year":"2024","journal-title":"Oncol Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1540013","article-title":"Multimodal deep learning for predicting PD-L1 biomarker and clinical immunotherapy outcomes of esophageal cancer","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02779-4","article-title":"Prognostic significance of PET\/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study","volume":"131","author":"Wang","year":"2024","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"B40","unstructured":"Neoadjuvant Checkpoint Blockade for Cancer Immunotherapy | Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1741482","article-title":"Impact of immune-related adverse events on treatment outcomes in advanced esophageal squamous cell carcinoma treated with immune checkpoint inhibitors","volume":"17","author":"Zhang","year":"2026","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1682377","article-title":"Comparison of short-term outcomes of combined neoadjuvant chemotherapy and immunotherapy, neoadjuvant radiotherapy, and neoadjuvant chemotherapy for resectable locally advanced esophageal squamous cell carcinoma","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1587658","article-title":"Safety and necessity of omitting mediastinal lymph node dissection in cN0\/N1 non-small cell lung cancer after neoadjuvant immunotherapy","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjon.2023.03.015","article-title":"The impact of neoadjuvant immunotherapy on perioperative outcomes and survival after esophagectomy for esophageal cancer","volume":"14","author":"Wong","year":"2023","journal-title":"JTCVS Open"},{"key":"B46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11864-018-0551-z","article-title":"Overview of current and future adjuvant therapy for muscle-invasive urothelial carcinoma","volume":"19","author":"Nadal","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_201227","article-title":"Multidisciplinary management of muscle-invasive bladder cancer: current challenges and future directions","volume":"38","author":"Aragon-Ching","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2021.02.099","article-title":"Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer","volume":"163","author":"Tong","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.12.019","article-title":"Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: prospective assessment of perioperative outcomes from the PURE-01 trial","volume":"77","author":"Briganti","year":"2020","journal-title":"Eur Urol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/or.2024.1435922","article-title":"Tumor therapeutics in the era of \u201cRECIST\u201d: past, current insights, and future prospects","volume":"18","author":"Xu","year":"2024","journal-title":"Oncol Rev"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000082","article-title":"Immune-related response criteria: light and shadows","volume":"1","author":"Merlano","year":"2016","journal-title":"ESMO Open"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0552-6","article-title":"Cancer immunotherapy beyond immune checkpoint inhibitors","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170457","article-title":"Immune-related tumour response assessment criteria: a comprehensive review","volume":"91","author":"Somarouthu","year":"2018","journal-title":"Br J Radiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40364-021-00306-8","article-title":"Imaging biomarkers for evaluating tumor response: RECIST and beyond","volume":"9","author":"Ko","year":"2021","journal-title":"biomark Res"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1186\/s12885-025-15258-7","article-title":"Prognostic performance of the nutritional risk screening 2002 and the global leadership initiative on malnutrition in patients with lung cancer treated with immune checkpoint inhibitors","volume":"25","author":"Wang","year":"2025","journal-title":"BMC Cancer"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00491","article-title":"A threshold model for T-cell activation in the era of checkpoint blockade immunotherapy","volume":"10","author":"Guram","year":"2019","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0161","article-title":"Immune checkpoint inhibitors and the exposome: host-extrinsic factors determine response, survival, and toxicity","volume":"83","author":"Pizzutilo","year":"2023","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100800","article-title":"Immune-related adverse events associated with cancer immunotherapy","volume":"6","author":"Kungwankiattichai","year":"2025","journal-title":"Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:36:16Z","timestamp":1783575376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1825905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2026.1825905"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1825905","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"article-number":"1825905"}}